Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
Study Details
Study Description
Brief Summary
This pilot clinical trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with kidney cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Stereotactic body radiation therapy Patients undergo stereotactic body radiation therapy on day 1 over 3 times a week for 28 days in the absence of disease progression or unacceptable toxicity. |
Radiation: Stereotactic Body Radiation Therapy
Undergo stereotactic body radiation therapy
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Incidence of radiation therapy (RT)-related grade >= 4 toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [Up to 1 year]
RT-related grade >= 4 toxicity will be determined on a case-by-case basis by the study group, taking into consideration the region treated with SBRT, timing of the toxicity, and the nature of the toxicity. Rates of RT-related grade >= 4 toxicity will be recorded, time to RT-related grade >= 4 toxicity will be recorded, and freedom from RT-related grade >= 4 toxicity will be determined using the Kaplan-Meier method.
Secondary Outcome Measures
- Treated lesion control (LeC), defined as absence of clinical or radiographic progression per Response Evaluation Criteria in Solid Tumors (RECIST) [From the start of treatment to the time of local progression at each treated lesion, assessed up to 1 year]
LeC will be estimated using descriptive statistics and the Kaplan-Meier method.
- Progression-free survival, defined as progression in the treated lesion, organ in which the treated lesion is present, distant failure, or death from any cause [From start of treatment to time of progression, assessed up to 1 year]
Progression is defined as any new sites of disease on imaging or any progressive disease by RECIST criteria at initially treated sites of disease (within 80% isodose line). PFS will be estimated using descriptive statistics and the Kaplan-Meier method.
- Toxicity profile of 5-fraction SBRT based on normal tissue dosimetric constraints based on the organ site of involvement [Up to 1 year]
Toxicities of interest that occur within the 3-12 month time frame after RT start will be documented and analyzed using descriptive statistics and the Kaplan-Meier method.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must have histologically or cytologically confirmed metastatic or recurrent RCC (any histologic subtype)
-
Patients must have between 1 to 5 new or recurrent lesions suspicious for metastatic RCC on diagnostic imaging
-
Each extracranial lesion must be =< 6 cm and amenable to SBRT or surgical excision
-
Patients must have 3 or fewer brain metastases, of size =< 4 cm
-
Brain metastases must be treated prior to enrollment in the study; the modality of treatment of brain metastases can include surgical resection, whole brain radiotherapy, stereotactic radiosurgery, or any combination of the above
-
Patients who have an intact unresected primary tumor should be considered for radical nephrectomy and primary resection prior to enrollment in the study; if the patient is not eligible for surgical resection, the primary tumor must be amenable to SBRT or request for applications (RFA); generally, this will be defined as a primary tumor < 10 cm in size or a primary lesion which can be treated to a dose of >= 8 Gy x 5 without excessive perceived risk of toxicity
-
Patients must have had at least a computed tomography (CT) of the chest, abdomen, and pelvis within 4 weeks of registration in the trial; CT or magnetic resonance imaging (MRI) of the brain is only required in the presence of neurologic symptoms
-
Patients must have had no radiotherapy, immunotherapy, chemotherapy or therapy with targeted agents within the last 1 month
-
Patients may not have had prior bevacizumab, based on case reports of tracheoesophageal fistula in patients treated with bevacizumab and radiotherapy
-
Eastern Cooperative Oncology Group (ECOG) performance status =<2
-
Age 18 years or older
-
Life expectancy of >= 3 months
-
Patients must have normal organ and marrow function within 30 days of registration, as defined below:
-
Absolute neutrophil count >= 500/mcL
-
Hemoglobin >= 8.0 g/dL
-
Platelets >= 50,000/mcL
-
Total bilirubin within normal institutional limits
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 X institutional upper limit of normal if liver metastases are present
-
Women of childbearing potential must have a negative pregnancy test within 14 days of registration
-
Patients must have the ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
-
Patients who have had prior chemotherapy, immunotherapy, targeted therapy, or radiotherapy within 1 month of enrollment
-
Patients who have had any prior bevacizumab, due to case reports suggesting a possible risk of severe toxicity in combination with radiotherapy
-
Patients with radiographic or clinical findings of spinal cord compression or cauda equina syndrome with neurologic deficit thought to be due to malignancy
-
Patients may not be receiving any systemic anti-cancer agents or other investigational agents during radiation therapy
-
Patients may not have received prior radiation therapy to a site of recurrence which would require overlap of appreciable radiation dose
-
Known active invasive malignancy except for renal cell carcinoma and/or non-melanoma skin cancer
-
Severe, active co-morbidity, defined as follows:
-
Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration;
-
Transmural myocardial infarction within the last 6 months prior to registration;
-
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;
-
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration;
-
Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease if the liver is involved with metastatic disease;
-
Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol
-
Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception during protocol treatment or for at least 6 months following treatment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Chicago Comprehensive Cancer Center | Chicago | Illinois | United States | 60637 |
Sponsors and Collaborators
- University of Chicago
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Stanley Liauw, University of Chicago Comprehensive Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB14-1542
- NCI-2015-01322
- IRB14-1542
- P30CA014599